A phase II study of ALLN-177 in adolescents and adults with primary hyperoxaluria or severe forms of secondary hyperoxaluria
Phase of Trial: Phase II
Latest Information Update: 16 Jan 2019
At a glance
- Drugs Reloxaliase (Primary)
- Indications Hyperoxaluria; Primary hyperoxaluria
- Focus Therapeutic Use
- Sponsors Allena Pharmaceuticals
- 07 Nov 2018 According to an Allena Pharmaceuticals media release, interim data from the trial is expected in the first half of 2019 and top-line data is expected in the second half of 2019.
- 23 Jul 2018 According to an Allena Pharmaceuticals media release, patient enrolment is expected to begin at European sites in the third quarter of 2018.
- 23 Jul 2018 According to an Allena Pharmaceuticals media release, first patient has been dosed.